Project Grant R41HL142384

Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a three-year Project Grant totaling $301,840 to The Regents of the University of California, San Francisco under the Cardiovascular Diseases Research program (CFDA 93.837) for the EPIC-LT (Eliminating PGD Through Inhibition of CCR5 in Lung Transplantation) initiative, effective August 1, 2025 through July 31, 2028. This project addresses primary graft dysfunction (PGD), which occurs in approximately...

This Project Grant, awarded July 1, 2026, by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), provides $731,287 in federal funding to The Regents of the University of California, San Francisco (UCSF) through March 31, 2030. The grant funds research investigating airway epithelial cell reprogramming mechanisms that drive chronic lung allograft dysfunction (CLAD), a progressive complication that limits survival following lung...

Duke University's Office of Research Administration received a $597,613 Project Grant awarded April 1, 2026, under the National Institute of Allergy and Infectious Diseases' Allergy and Infectious Diseases Research program (CFDA 93.855). The five-year project, concluding March 31, 2031, delivers research and development services focused on ex vivo gene therapy delivery to prevent post-transplant rejection in lung grafts. The research involves developing and testing adeno-associated virus...

Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 (Cardiovascular Diseases Research) awarded $233,250 to The Washington University in St. Louis on June 15, 2026, with completion targeted for May 31, 2028. This Project Grant funds research investigating the mechanisms by which mycophenolic acid (MPA)—an immunosuppressant medication used by over 80% of lung transplant recipients—induces neutropenia, a serious adverse effect characterized by...

Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Regents of the University of California, San Francisco a Project Grant of $795,464 (award date: July 1, 2026; completion date: March 31, 2031) under the Cardiovascular Diseases Research program (CFDA 93.837). This research project investigates adaptive-like natural killer (NK) cells in pulmonary cytomegalovirus (CMV) reactivation, a critical clinical concern given CMV's association with...

Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Pennsylvania a $1,537,686 Project Grant on August 25, 2025, through the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate computed tomography (CT)-based measures of body composition for improved risk assessment in lung transplant candidate selection and organ allocation. The research addresses the critical knowledge gap regarding integration of adipose tissue...

Summary The University of Iowa received a $660,875 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded April 1, 2026, with completion targeted for March 31, 2028. The grant funds research investigating transforming growth factor-beta (TGF-β) signaling mechanisms in lymphangioleiomyomatosis (LAM), a progressive and debilitating lung disease with limited therapeutic options. The research deliverables...

Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of South Alabama a Project Grant of $761,262 under the Cardiovascular Diseases Research program (CFDA 93.837) for the period September 1, 2025 through June 30, 2029. This research project investigates the protective mechanisms of intravenously injected bone marrow-derived mesenchymal stromal cells (BMSCs) against acute lung injury (ALI), with the primary objective of understanding how...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant of $174,744 to the University of California, San Francisco on June 2, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support fundamental research on acute lung injury modulation. The research investigates the immunoregulatory role of the phosphatase SHP1 (Src Homology Region 2 Domain-Containing Phosphatase-1) in acute respiratory distress syndrome and acute lung injury, with the ultimate...

Federal Project Grant Award Summary Duke University received a $158,652 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through August 31, 2030. This award supports research investigating the post-lung transplant impact of alveolar macrophage senescence in aged donor lungs. The research addresses a critical clinical challenge: as the demand for lung transplantation has...